Eli Lilly To Buy Calytrix Bio For Up To $1.5 Billion

Calytrix Bio, a biotechnology company developing precision treatments for myeloproliferative neoplasms, has entered into a definitive agreement for Eli Lilly to acquire it for up to $1.5 billion in cash. The transaction will give Lilly access to Calytrix’s preclinical antibody program targeting mutant calreticulin, with the goal of developing disease-modifying medicines for essential thrombocythemia and myelofibrosis.

The purchase agreement includes an upfront cash payment and additional payments tied to specified clinical and regulatory milestones.

The total potential consideration of $1.5 billion depends on achievement of those milestones rather than representing a fully guaranteed upfront purchase price.

Calytrix is focused on myeloproliferative neoplasms, a group of blood disorders involving abnormal production of blood cells.

Its initial therapeutic programs address essential thrombocythemia and myelofibrosis associated with mutations in calreticulin, known as mCALR.

Essential thrombocythemia can involve excessive platelet production, while myelofibrosis affects bone marrow function and can cause significant clinical complications.

Existing therapies frequently focus on managing symptoms and reducing complications.

Calytrix is developing an alternative approach intended to target the underlying disease-driving mutations.

Developing An Antibody Against Mutant Calreticulin

Calytrix’s lead asset is an investigational biparatopic antibody designed to recognize mutant calreticulin.

A biparatopic antibody can bind to two distinct regions of a molecular target.

The company’s program is designed to target both Type 1 and Type 2 mCALR mutations, which are associated with certain myeloproliferative neoplasms.

Mutant calreticulin provides a potential tumor-specific cell-surface target.

Calytrix aims to develop a therapy capable of eliminating disease-driving mutant cell populations while preserving healthy blood-forming tissues.

The approach could potentially support earlier intervention and longer-term treatment if future studies establish an acceptable safety and efficacy profile.

However, the program remains preclinical and has not yet demonstrated clinical benefits in patients.

Expanding Lilly’s Blood Cancer Research

The acquisition will expand Lilly’s presence in myeloproliferative neoplasms and complement its existing capabilities in blood cancers.

Lilly intends to advance Calytrix’s lead program into clinical development and investigate its potential across relevant patient populations.

The transaction is designed to accelerate work on a precision medicine approach that targets a disease-associated mutation rather than primarily addressing its downstream symptoms.

Calytrix President and CEO Brad Prosek said the company was established with the goal of changing disease progression in patients with mCALR-driven essential thrombocythemia and myelofibrosis.

Company Formation And Financing

Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm of J.P. Morgan Asset Management.

The company launched with Series A financing co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners.

It subsequently completed a Series B financing led by Avoro Ventures.

The proposed sale to Lilly follows a relatively short period of company development focused on advancing its lead therapeutic program toward clinical testing.

Centerview Partners is serving as exclusive financial advisor to Calytrix, while Goodwin Procter is acting as its legal counsel.

Paul, Weiss, Rifkind, Wharton & Garrison is serving as legal counsel to Lilly.

The agreement represents a substantial potential investment in next-generation therapies for serious blood disorders and provides Lilly with an additional precision medicine program in its oncology research portfolio.

KEY QUOTE:

“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s program to the starting line for clinical development.”

Brad Prosek, President And CEO Of Calytrix Bio